FDA in focus: 2024 in review and 2025 outlook

Start
In 2024, the Food and Drug Administration (FDA) significantly invested in reorganizing its internal infrastructure and enhancing operations. These efforts aimed to address the complexities of a global supply chain, rapid innovation in product development and artificial intelligence (AI), and a strong focus on the safety and labeling of FDA-regulated products….
By: DLA Piper
Previous Story

The Longleaf Network Experiences Data Breach Following May 2024 Cyberattack

Next Story

Data Minimization: A Legally Required Tool to Mitigate Risk